The Changing Landscape of Ulcerative Colitis: Identification, Methods of Treatment and Implications in the COVID-19 Era

1.25 CME
1.25 CNE
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact



BUCME logo
Provided by Boston University School of Medicine

Release Date: 8/31/20
Expiration Date: 8/30/21

Credit Types: CME, CNE, AAPA, ABCGN
Number of credits: 1.25
Estimated time to complete: 75 minutes

Activity Format

This activity is a 75-minute on-demand webcast of a live webinar presentation that was recorded on 7/30/20. The presentation is an interactive roundtable discussion in a video/slide format featuring a panel of UC faculty experts. The didactic presentation is centered around an actual patient case and is followed by an audience Q+A session.  

Activity Description

As an inflammatory condition, the management of ulcerative colitis (UC) in the current COVID-19 landscape is important as are several other elements of UC. With the growing number of UC patients, gastroenterology teams that include gastroenterologists, GI surgeons, nurses, nurse practitioners (NPs), physician assistants (PAs), and other valuable practitioners together will be essential to provide care for the increasing patient population.

It is vital that clinicians who manage a patient population on medications affecting the host inflammatory and immune responses be informed regarding adaptive ways to keep their patients safe. Centered on actual patient cases, this continuing education activity aims to provide UC care team members with the latest data regarding:

  • Managing UC in the COVID-19 landscape;
  • Insights into inflammation and the current pandemic;
  • AASLD, ACG, AGA, and ASGE recent guideline updates;
  • Potential mechanisms: ACE2 pathway; immunosuppressive therapy; others;
  • Strategies for re-focusing care in UC; 
  • Overcoming barriers and adapting to changing treatment goals;
  • Assessing novel treatments and future directions; and
  • Best practices for team-based care approaches with improved patient communication.

Target Audience

Integral members of the multidisciplinary IBD patient care team including gastroenterologists, GI surgeons, NP/PAs, and nurses.

Educational Objectives

At the conclusion of this activity, participants will be able to (or better able to):

  • Evaluate key considerations and the latest emerging data for managing ulcerative colitis and its associated comorbidities in the era of COVID-19.
  • Describe several ways in which the management of UC has changed over the past two years, and ways to adapt to these changes in practice.
  • Review current and evolving agents used for UC, regarding pharmacokinetics, efficacy, safety, and overall role in UC management.
  • Assess ways in which to improve comprehensive UC care through communication with patients and involvement of other individuals on the care team.

Accreditor Disclosure Policy

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Nursing Continuing Professional Development (NCPD) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.  

Program Faculty

Sharmeel Wasan
Sharmeel K. Wasan, MD
Course Director
Fellowship Director, Section of Gastroenterology
Boston Medical Center
Assistant Professor of Medicine
Boston University School of Medicine

Dr. Wasan has no relevant financial relationships to disclose.

Faculty member does plan on discussing unlabeled/investigational uses of a commercial product.

Sharmeel K Wasan, MD, FACG is a clinician-educator with an expertise in Inflammatory Bowel Diseases (IBD) and an Assistant Professor of Medicine at Boston University. She completed her clinical training at Boston Medical Center, the Brigham and Women’s Hospital, and the University of Maryland. She received her BS in Biological Sciences and BA in Anthropology from Stanford University in Palo Alto, CA and received her MD from Albert Einstein College of Medicine in New York. As the Gastroenterology Program Director at Boston Medical Center, she is actively involved in the training of fellows, residents, and medical students. Her current clinical and research interests include vaccination strategies, health care maintenance in patients with IBD, and educational strategies in endoscopy training. She has received research and educational grants from BU and from industry supported funding.

Jospeh Feuerstein
Joseph D. Feuerstein, MD
Associate Clinical Chief, Gastroenterology
Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Feuerstein has no relevant financial relationships to disclose.

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.

Joseph Feuerstein earned his M.D. from Boston University School of Medicine with cum laude honors. Dr. Feuerstein completed his internship and residency in internal medicine at Boston Medical Center followed by a chief residency year also at Boston Medical Center. Subsequently, Dr. Feuerstein completed a fellowship in gastroenterology at Beth Israel Deaconess Medical Center while also serving as a fellow in inflammatory bowel disease and chief fellow.  

Dr. Feuerstein is currently the Associate Clinical Chief of Gastroenterology and a member of the Inflammatory Bowel Disease Center at Beth Israel Deaconess Medical Center as well as an Assistant Professor of Medicine at Harvard Medical School. 

He specializes in improving quality in gastroenterology and in inflammatory bowel disease. His clinical interests include quality improvement, clinical practice guidelines, and inflammatory bowel disease. He has published multiple original research articles, review articles, and chapters. He has authored multiple national inflammatory bowel disease guidelines and has been the editor on multiple books on inflammatory bowel disease.  

Dr. Feuerstein is actively involved in teaching medical students, residents and gastroenterology fellows at Harvard Medical School and Beth Israel Deaconess Medical Center. He is involved in the daily teaching of gastroenterology fellows in clinic and in endoscopy. He has mentored gastroenterology fellows in multiple research projects. 

He has received multiple teaching awards, research awards, and awards in clinical practice of inflammatory bowel disease patients.  Dr. Feuerstein is an active member of the Crohn’s and Colitis Foundation of America (CCF), American Gastroenterological Association (AGA) American College of Gastroenterology (ACG) and American Society of Gastrointestinal Endoscopy (ASGE). He is active in multiple committees for the AGA, ACG, and CCF.

Ryan Ungaro
Ryan Ungaro, MD
The Susan and Leonard Feinstein IBD Center
Mount Sinai Hospital
Assistant Professor of Medicine
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York City, New York

Dr. Ungaro is a consultant for Abbvie, Eli Lilly, Janssen, Pfizer and Takeda; he also receives research support fro Abbvie, Boehringer  Ingelheim and Pfizer. 

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.

Dr. Ryan Ungaro is an Assistant Professor of Medicine in the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai. Dr. Ungaro received his undergraduate degree from Wesleyan University and his medical degree from the Icahn School of Medicine at Mount Sinai where he graduated Alpha Omega Alpha and with Distinction in Research. He completed his internal medicine training and served as chief resident at the Mount Sinai Medical Center then went on to complete fellowship training in gastroenterology at the Mount Sinai Medical Center and served as chief gastroenterology fellow. Dr. Ungaro received training in translational inflammatory bowel disease (IBD) research as a Howard Hughes Medical Institute Research Fellow and completed a Masters in Biostatistics and Clinical Research Methods at Columbia University Mailman School of Public Health.

Dr. Ungaro specializes in the care of patients with ulcerative colitis and Crohn's disease. He is Director of the Comprehensive Care for the Recently Diagnosed IBD Patient (COMPASS-IBD) Program at the Susan and Leonard Feinstein IBD Clinical Center. This program provides interdisciplinary care for recently diagnosed inflammatory bowel disease (IBD) patients. His research focuses on understanding early IBD including the impact of early intervention on IBD outcomes and precision medicine approaches to improve risk stratification and optimization of therapy for recently diagnosed IBD patients. His work is supported by an NIH K23 Career Development Award and a Crohn's and Colitis Foundation Career Development Award. 

He is also a co-founder of the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) database, an international registry that aims to understand the impact of COVID-19 on IBD patients. 

Dr. Ungaro is on the staff of contributors for the Gastroenterology Selected Summaries Section and is a member of national committees including the AGA Research Awards Panel and the Rising Educators Academics and Clinicians Helping IBD (REACH-IBD) Committee of the Crohn's and Colitis Foundation. He has received various distinctions including being selected for the AGA Future Leaders Program, the Eric R. Lemmer Memorial Award and the Cullman Family Award for Excellence in Physician Communication.

Accreditor Disclosures

The following planning committee members from Boston University School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships to disclose: 

Juanita Belton, PA; AAPA Content Reviewer
Michael Burk, BS; Senior Program Manager
Christopher Drury, MA, MS; Consultant Medical Editor
Dana Frazier-Price MS, CHCP; Grant Development Manager
Bret Lashner, MD; CME Course Director and Professor of Medicine at Cleveland Clinic
Carmela A. Townsend, DNP, MS/MBA, RN, Lead Nurse Planner

Beth-Ann Norton, MS, RN, ANP-BC, Nurse Advisor, Boston University School of Medicine Office of Continuing Medical Education, is on the advisory board for Pfizer Inc. 

Accreditation Information

CME Accreditation
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCPD Accreditation 
Boston University School of Medicine Continuing Nursing Education Provider Unit is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Contact Hours: 1.25, all is eligible for pharmacology credit

AAPA Accreditation

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME Credits. Approval is valid from 8/31/2020 to 8/30/2021. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-200822.

ABCGN Accreditation
According to the criteria of the American Board of Certification for Gastroenterology Nurses (ABCGN), the approved hours in this activity are considered GI Specific for the purpose of recertification by contact hours through the ABCGN.

Contact Hours: 1.25 G.I. Specific Category 5 hours


This activity is supported by an independent educational grant from Pfizer Inc. 



How to Claim Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.25 AMA PRA Category 1 Credit™, nurses are entitled to receive 1.25 CNE contact hours, physician assistants are entitled to receive 1.25 AAPA Category 1 CME credits and gastroenterological nurses are entitled to receive 1.25 G.I. Specific Category 5 hours. Certificates of credit will be awarded following completion of the posttest and evaluation through the supplied link. The certificates of credit will be available for immediate download and will also be emailed to participants. 

In order to claim credit please:

  • Review the activity front matter and faculty disclosures
  • Watch the presentation 
  • Complete the post-test and activity evaluation
  • Physicians, nurses and physician assistants who successfully complete the post-test and evaluation will respectively receive CME. You must score a 80% or higher on the post-test to receive credit for this activity. Please note that you will be able to take the posttest three times. 
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

For questions about CME, please contact or

To view Boston University’s Privacy Policy, please see

© Trustees of Boston University, 2020